These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


328 related items for PubMed ID: 7560592

  • 1. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP, Paul T, Lehmann C, Kallfelz HC.
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [Abstract] [Full Text] [Related]

  • 2. [Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias].
    Paul T, Lehmann C, Pfammatter JP, Kallfelz HC.
    Z Kardiol; 1994 Dec; 83(12):891-7. PubMed ID: 7531374
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH, van de Loo A, Baedeker F.
    J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
    [Abstract] [Full Text] [Related]

  • 4. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW.
    N Engl J Med; 1993 Aug 12; 329(7):452-8. PubMed ID: 8332150
    [Abstract] [Full Text] [Related]

  • 5. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP, Paul T.
    Pediatr Cardiol; 1997 Aug 12; 18(1):28-34. PubMed ID: 8960489
    [Abstract] [Full Text] [Related]

  • 6. Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol.
    Rao SO, Boramanand NK, Burton DA, Perry JC.
    Int J Cardiol; 2009 Aug 21; 136(3):253-7. PubMed ID: 18653253
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M, Haverkamp W, Shenasa M, Hindricks G, Breithardt G.
    J Cardiovasc Pharmacol; 1992 Aug 21; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [Abstract] [Full Text] [Related]

  • 13. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J.
    J Am Coll Cardiol; 1995 Sep 21; 26(3):787-92. PubMed ID: 7642874
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and adverse effects of sotalol in adults with congenital heart disease.
    Moore BM, Cordina RL, McGuire MA, Celermajer DS.
    Int J Cardiol; 2019 Jan 01; 274():74-79. PubMed ID: 29954667
    [Abstract] [Full Text] [Related]

  • 17. [Combination anti-arrhythmic drug therapy].
    Lüderitz B, Jung W, Manz M.
    Z Kardiol; 1992 Jan 01; 81 Suppl 4():157-61. PubMed ID: 1283933
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH, Sandøe E.
    Ugeskr Laeger; 1996 May 06; 158(19):2711-6. PubMed ID: 8744073
    [Abstract] [Full Text] [Related]

  • 20. Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
    Chandler SF, Chu E, Whitehill RD, Bevilacqua LM, Bezzerides VJ, DeWitt ES, Alexander ME, Abrams DJ, Triedman JK, Walsh EP, Mah DY.
    Heart Rhythm; 2020 Jun 06; 17(6):984-990. PubMed ID: 32014568
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.